Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee
April 12, 2002
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Cozaar™ (losartan) in Type 2 Diabetes and Nephrophathy, Michael C. Elia, PhD, Merck Research Laboratories ppt htm